Y-mabs Therapeutics

DANYELZA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Y-mabs Therapeutics

Danyelza HCPCS:

J9348

HCPCS Code Descriptor:

Injection, naxitamab-gqgk, 1 mg

Category:

J Code

Danyelza NDCs:

73042-0201-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Danyelza CPT Codes:

-96413 - Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance

-96415 - Chemotherapy administration, intravenous infusion technique; each additional hour

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Danyelza:

DANYELZA is an Oncology drug manufactured by Y-mabs Therapeutics and administered via the Intravenous route of administration. The J Code: J9348 is aligned to the drug DANYELZA.

ACCESS PRICING AND MORE BY REGISTERING

J9348 Added Date:

July 1, 2021

J9348 Effective Date:

July 1, 2021

J9348 Termination Date:

HCPCS Active

Danyelza billing and coding information can be found through Y-Mabs Therapeutics at the link below:
Danyelza patient assistance information can be found through Y-mAbs Connect at the URL: https://ymabsconnect.com/
DANYELZA prescribing information can be found at the link below:
Information regarding DANYELZA’s side effects can be found at MedlinePlus